Abstract
The efficacies of tigecycline and ceftazidime against fatal pneumonia in rats caused by an extended-spectrum β-lactamase (ESBL)-positive Klebsiella pneumoniae strain or its wild-type (WT) progenitor were compared. Ceftazidime at 12.5 or 50 mg/kg of body weight twice daily (b.i.d.) was effective (50% or 100% rat survival) in pneumonia caused by the WT isolate but unsuccessful (100% rat mortality) in pneumonia caused by the ESBL-positive variant. In contrast, tigecycline at 6.25, 12.5, or 25 mg/kg b.i.d. showed dosage-dependent efficacy up to 100% rat survival irrespective of the ESBL character of the infecting organism.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anti-Bacterial Agents / blood
-
Anti-Bacterial Agents / pharmacokinetics
-
Anti-Bacterial Agents / pharmacology*
-
Area Under Curve
-
Ceftazidime / pharmacology
-
Dose-Response Relationship, Drug
-
Klebsiella Infections / blood
-
Klebsiella Infections / drug therapy*
-
Klebsiella Infections / microbiology
-
Klebsiella Infections / mortality
-
Klebsiella pneumoniae / drug effects*
-
Klebsiella pneumoniae / growth & development
-
Lung / drug effects*
-
Lung / microbiology
-
Male
-
Microbial Sensitivity Tests
-
Minocycline / analogs & derivatives*
-
Minocycline / blood
-
Minocycline / pharmacokinetics
-
Minocycline / pharmacology
-
Pneumonia, Bacterial / blood
-
Pneumonia, Bacterial / drug therapy*
-
Pneumonia, Bacterial / microbiology
-
Pneumonia, Bacterial / mortality
-
Rats
-
Survival Analysis
-
Tigecycline
-
beta-Lactamases / biosynthesis*
Substances
-
Anti-Bacterial Agents
-
Tigecycline
-
Ceftazidime
-
beta-Lactamases
-
Minocycline